Latest News and Press Releases

Dublin, May 12, 2026 (GLOBE NEWSWIRE) -- The "The Global Quantum Technology Market 2026-2046: Computing, Sensors, Communications & Software" report has been added to ResearchAndMarkets.com's...

Top-line data from the Phase 3 OPERA-01 trial anticipated this fall; Phase 3 OPERA-02 trial continues to enroll patientsFirst clinical data from OP-3136 Phase 1 study to be presented at ASCO Ended the...

On track to report topline data from Phase 3 LEVEL study of TNX-103 in third quarter of 2026 Global Phase 3 LEVEL-2 clinical trial ongoing, enrollment completion anticipated by end of 2027 ...

Addition Therapeutics presents preclinical proof-of-concept data at American Society of Gene & Cell Therapy (ASGCT) 29th Annual Meeting in Boston.

Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026IND clearance of ARR-002, ArriVent’s dual-targeting MUC16/NaPi2b tetravalent...

New York, USA, May 11, 2026 (GLOBE NEWSWIRE) -- Presbyopia Market to Witness Accelerated Growth at a CAGR of 4.9% During the Forecast Period (2026–2036) Supported by Expanding Treatment Landscape |...

Dublin, May 11, 2026 (GLOBE NEWSWIRE) -- The "Ranibizumab Market Report 2026" has been added to ResearchAndMarkets.com's offering. The Ranibizumab Market Global Report 2026 is an essential...

-Acoramidis increased sTTR early and significantly reduced intra-individual sTTR variability versus placebo (p<0.001), which is associated with reduced ACM, further reinforcing its differentiated...

AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: The ability to accurately detect drug and alcohol intoxication has long been a persistent challenge across industries,...

GLEN ALLEN, Va., May 11, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...